IL266473B - 3-substituted propionic acids as alpha v integrin inhibitors - Google Patents

3-substituted propionic acids as alpha v integrin inhibitors

Info

Publication number
IL266473B
IL266473B IL266473A IL26647319A IL266473B IL 266473 B IL266473 B IL 266473B IL 266473 A IL266473 A IL 266473A IL 26647319 A IL26647319 A IL 26647319A IL 266473 B IL266473 B IL 266473B
Authority
IL
Israel
Prior art keywords
alpha
propionic acids
integrin inhibitors
substituted propionic
substituted
Prior art date
Application number
IL266473A
Other languages
Hebrew (he)
Other versions
IL266473A (en
Inventor
Michael F Parker
Suresh Dhanusu
Kumaravel Selvakumar
Pratik Devasthale
Guohua Zhao
Xiang-Yang Ye
Palanikumar Balasubramanian
Leatte R Guernon
Rita Civiello
Xiaojun Han
Swanee E Jacutin-Porte
Original Assignee
Bristol Myers Squibb Co
Michael F Parker
Suresh Dhanusu
Kumaravel Selvakumar
Pratik Devasthale
Guohua Zhao
Ye Xiang Yang
Palanikumar Balasubramanian
Leatte R Guernon
Rita Civiello
Xiaojun Han
Jacutin Porte Swanee E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Michael F Parker, Suresh Dhanusu, Kumaravel Selvakumar, Pratik Devasthale, Guohua Zhao, Ye Xiang Yang, Palanikumar Balasubramanian, Leatte R Guernon, Rita Civiello, Xiaojun Han, Jacutin Porte Swanee E filed Critical Bristol Myers Squibb Co
Publication of IL266473A publication Critical patent/IL266473A/en
Publication of IL266473B publication Critical patent/IL266473B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL266473A 2016-11-08 2019-05-06 3-substituted propionic acids as alpha v integrin inhibitors IL266473B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662418848P 2016-11-08 2016-11-08
PCT/US2017/060376 WO2018089353A1 (en) 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors

Publications (2)

Publication Number Publication Date
IL266473A IL266473A (en) 2019-07-31
IL266473B true IL266473B (en) 2022-06-01

Family

ID=60409432

Family Applications (1)

Application Number Title Priority Date Filing Date
IL266473A IL266473B (en) 2016-11-08 2019-05-06 3-substituted propionic acids as alpha v integrin inhibitors

Country Status (29)

Country Link
US (2) US10968219B2 (en)
EP (1) EP3538525B1 (en)
JP (1) JP7097358B2 (en)
KR (1) KR102505629B1 (en)
CN (1) CN110167935B (en)
AR (1) AR110153A1 (en)
AU (1) AU2017359023B2 (en)
CL (1) CL2019001264A1 (en)
CO (1) CO2019005824A2 (en)
DK (1) DK3538525T3 (en)
EA (1) EA038164B1 (en)
ES (1) ES2925173T3 (en)
HR (1) HRP20220990T1 (en)
HU (1) HUE059708T2 (en)
IL (1) IL266473B (en)
LT (1) LT3538525T (en)
MA (1) MA46743A (en)
MX (1) MX380799B (en)
MY (1) MY199931A (en)
NZ (1) NZ754207A (en)
PE (1) PE20191647A1 (en)
PL (1) PL3538525T3 (en)
PT (1) PT3538525T (en)
RS (1) RS63483B1 (en)
SI (1) SI3538525T1 (en)
SM (1) SMT202200338T1 (en)
TW (1) TWI763733B (en)
WO (1) WO2018089353A1 (en)
ZA (1) ZA201903665B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604520B2 (en) 2016-09-07 2020-03-31 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
WO2018089353A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
CA3042710A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
BR112019009245A2 (en) * 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amides and amines as alfav integrin inhibitors
KR20190100232A (en) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 Integrin antagonists
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
IL316954A (en) 2017-02-28 2025-01-01 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
UY38353A (en) 2018-08-29 2020-03-31 Morphic Therapeutic Inc INHIBITION OF INTEGRIN ALFAVBETA6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
UY38352A (en) 2018-08-29 2020-03-31 Morphic Therapeutic Inc INTEGRIN INHIBITORS ALFAVBETA6
HUE070112T2 (en) 2018-10-30 2025-05-28 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dione derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
JP7189369B2 (en) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド Compounds for inhibition of alpha4beta7 integrin
CN112996786B (en) 2018-10-30 2024-08-20 吉利德科学公司 Compounds for inhibiting α4β7 integrin
CN109824495B (en) * 2019-02-02 2022-12-09 盐城师范学院 Application of novel coupling reaction in preparation of carbon-carbon bond structure compound
JP7491996B2 (en) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド Compounds for the inhibition of alpha4beta7 integrin
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
TW202513065A (en) * 2023-09-21 2025-04-01 美商莫菲克醫療股份有限公司 INHIBITING HUMAN INTEGRIN α5β1

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451790A1 (en) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituted 2-isoxazolines and isoxazoles, process for their preparation, medicines containing them and their use
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
AU1523199A (en) 1997-11-26 1999-06-15 Du Pont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists
EP1047425A4 (en) 1997-12-17 2009-04-22 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTOR
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
WO2004058761A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
BR0317600A (en) * 2002-12-20 2005-11-29 Pharmacia Corp heteroarylalkanoic acids as derivatives of integrin receptor antagonists
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR059224A1 (en) 2006-01-31 2008-03-19 Jerini Ag COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
CN102482225B (en) 2009-09-04 2016-10-05 巴斯夫欧洲公司 The method preparing 1-phenyl pyrazoles
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
ITFI20100019A1 (en) 2010-02-12 2011-08-13 Univ Firenze INTEGRINE PEPTIDOMYMETIC INHIBITORS BASED ON 1,2,3-TRIAZOL FOR DIAGNOSIS AND THERAPY OF TUMORS.
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (en) 2013-12-19 2019-08-01 德商拜耳製藥公司 Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
CA2981371A1 (en) * 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
WO2018089353A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors

Also Published As

Publication number Publication date
AR110153A1 (en) 2019-02-27
HUE059708T2 (en) 2022-12-28
EP3538525A1 (en) 2019-09-18
CN110167935A (en) 2019-08-23
JP2019537594A (en) 2019-12-26
LT3538525T (en) 2022-09-26
CA3042707A1 (en) 2018-05-17
HRP20220990T1 (en) 2022-11-11
IL266473A (en) 2019-07-31
TW201823244A (en) 2018-07-01
MX380799B (en) 2025-03-12
EA038164B1 (en) 2021-07-16
PE20191647A1 (en) 2019-11-07
NZ754207A (en) 2025-09-26
ES2925173T3 (en) 2022-10-14
AU2017359023B2 (en) 2021-12-09
US11884661B2 (en) 2024-01-30
AU2017359023A1 (en) 2019-06-20
CL2019001264A1 (en) 2019-09-13
PT3538525T (en) 2022-08-16
JP7097358B2 (en) 2022-07-07
CN110167935B (en) 2022-05-27
US20210188847A1 (en) 2021-06-24
SI3538525T1 (en) 2022-09-30
KR102505629B1 (en) 2023-03-02
US10968219B2 (en) 2021-04-06
WO2018089353A1 (en) 2018-05-17
KR20190073554A (en) 2019-06-26
MY199931A (en) 2023-11-29
TWI763733B (en) 2022-05-11
RS63483B1 (en) 2022-09-30
MA46743A (en) 2019-09-18
CO2019005824A2 (en) 2019-06-11
ZA201903665B (en) 2022-12-21
EP3538525B1 (en) 2022-06-22
MX2019005244A (en) 2019-08-05
EA201991122A1 (en) 2019-10-31
PL3538525T3 (en) 2022-09-12
SMT202200338T1 (en) 2022-09-14
US20190263808A1 (en) 2019-08-29
DK3538525T3 (en) 2022-08-29

Similar Documents

Publication Publication Date Title
ZA201903665B (en) 3-substituted propionic acids as alpha v integrin inhibitors
EP3193608A4 (en) Carm1 inhibitors and uses thereof
EP3200588A4 (en) Arginine methyltransferase inhibitors and uses thereof
EP3193611A4 (en) Mk2 inhibitors and uses thereof
EP3175023A4 (en) Systems and methods for determining nucleic acids
EP3134536A4 (en) Systems and methods for barcoding nucleic acids
IL267239A (en) Novel phenyl propionic acid derivatives and uses thereof
EP3190682A4 (en) Power supply system and method
EP3229899A4 (en) Methods and apparatus for electrosurgical illumination and sensing
PL3218378T3 (en) 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
EP3181085A4 (en) Tracking system and tracking method using same
EP3102189A4 (en) Composition and method for aiding sleep
EP3153561A4 (en) Composition for heat cycle system and heat cycle system
EP3153567A4 (en) Composition for heat cycle system and heat cycle system
EP3162276A4 (en) System and method for managing endoscopic scope
EP3238840A4 (en) Method for recycling used absorbent article
EP3166523A4 (en) Cryoablation method and system
EP3155399A4 (en) Viscometer and methods for using the same
IL255054A0 (en) Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
EP3141930A4 (en) Distance-measurement device and method for powering distance-measurement device
AU359093S (en) Apparatus for sleep information detection
EP3387192A4 (en) An apparatus for water supply and sanitary purposes
EP3195129A4 (en) Application centric distributed storage system and method
EP3121932A4 (en) Power supply device and non-contact power supply system
EP3185880A4 (en) Improved peptidyl calcineurin inhibitors